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Translationally-controlled tumor-associated protein (TCTP)
has been discovered in 1983 in mouse erythroleukemia cells.
Over the years, it became evident that TCTP is an important
player in a number of basic cell physiology events in cancer,
embryo development, cell cycle, apoptosis, proliferation,
growth, stress response, allergy, gene regulation, and heat-
shock response. However, despite the nearly three decades
of research, we only start to understand the role of TCTP in
physiology of animal and plant embryo development as well
as in numerous pathologies through its participation in cell
cycle, proliferation, and growth regulation. The exact roles
of TCTP in many complex cellular processes still remain a
mystery. One of the key questions in cancer research is the
role of TCTP in tumor reversion, the rare event leading to
tumor regression and a “miraculous” cure: is TCTP involved
in gene regulation or rather modiﬁcation of the cytoskeleton
of cancer cells during this process? It seems plausible that
a novel type of posttranslational modiﬁcation of TCTP,
such as SUMOylation, by regulating its nuclear localization
and/or its association with the centrosomes (both subjects
featured in this issue) is responsible for some of the TCTP
functions in normal and cancer cells. From presented in this
issue very comprehensive and up-to-date reviews on TCTP
functions, it clearly transpires that TCTP has a potential to
be a crucial target for anticancer therapies. However, more
research on the regulation of TCTP and its involvement in
various molecular and cellular pathways and its association
with subcellular structures is needed for the improvement
of our understanding of this oncogene and the development
of novel TCTP-targeted cancer therapies. We hope that our
special TCTP issue will help in stimulation of scientiﬁc
research in this ﬁeld.
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